Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | F10 | P00742 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209054 | 0.86 | ALDH1A1 (0.61) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL2639481 | 0.84 | F10 (0.52) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL1678414 | 0.84 | F10 (0.49) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL1627878 | 0.82 | HPGD (0.54) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL27923490 | 0.81 | HPGD (0.37) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL1626763 | 0.81 | ALDH1A1 (0.54) | PTGS2F10ALDH1A1HPGD | |
| SCHEMBL19647445 | 0.81 | F10 (0.62) | PTGS2F10 | |
| SCHEMBL19086541 | 0.80 | PTGS2 (0.64) | PTGS2F10 | |
| SCHEMBL28956907 | 0.80 | PTGS2 (0.67) | PTGS2F10 | |
| SCHEMBL76558 | 0.78 | F10 (0.58) | PTGS2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103360380-B | A kind of synthetic method of razaxaban and the intermediate of razaxaban and preparation thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103360380-A | Synthesis method of rivaroxaban, and rivaroxaban intermediate and preparation thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO LTD | 2013-10-23 | — | — | CN | disclosed |